T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1976
Arrow Financial
AROW
$723M
| $1.24M | ﹤0.01% |
39,598
+13,049
| +49% | +$386K |
|
1977
Theravance Biopharma
TBPH
$878M
| $1.24M | ﹤0.01% |
66,109
+1,969
| +3% | +$32.7K |
|
1978
Lucid Motors
LCID
$2.54B
| $1.23M | ﹤0.01% |
116,719
+21,530
| +23% | +$344K |
|
1979
REX American Resources
REX
$1.44B
| $1.23M | ﹤0.01% |
38,131
-37
| -0.1% | -$1.21K |
|
|
KW
1980
DELISTED
Kennedy-Wilson Holdings
KW
| $1.23M | ﹤0.01% |
127,404
+4,409
| +4% | +$39.5K |
|
1981
ManpowerGroup
MAN
$2.75B
| $1.23M | ﹤0.01% |
41,376
+5,905
| +17% | +$184K |
|
|
BULL
1982
Webull Corp
BULL
$4.23B
| $1.22M | ﹤0.01% |
+157,150
| New | +$1.58M |
|
1983
Leggett & Platt
LEG
$1.29B
| $1.22M | ﹤0.01% |
110,788
-14,927
| -12% | -$147K |
|
1984
NovoCure
NVCR
$2.02B
| $1.22M | ﹤0.01% |
94,094
-16,212
| -15% | -$208K |
|
1985
Stepan Co
SCL
$1.48B
| $1.22M | ﹤0.01% |
25,687
+5,065
| +25% | +$232K |
|
|
THS
1986
DELISTED
Treehouse Foods
THS
| $1.22M | ﹤0.01% |
51,553
+332
| +0.6% | +$7.25K |
|
1987
STAAR Surgical
STAA
$1.26B
| $1.21M | ﹤0.01% |
52,535
+1,234
| +2% | +$31.8K |
|
1988
Bank of N.T. Butterfield & Son
NTB
$2.5B
| $1.2M | ﹤0.01% |
24,161
+1,923
| +9% | +$88.6K |
|
1989
GoodRx Holdings
GDRX
$1.27B
| $1.2M | ﹤0.01% |
442,668
+51,243
| +13% | +$168K |
|
|
EFC
1990
Ellington Financial
EFC
$1.76B
| $1.2M | ﹤0.01% |
88,281
+3,602
| +4% | +$49K |
|
1991
Organon & Co
OGN
$3.6B
| $1.2M | ﹤0.01% |
167,121
-40,728
| -20% | -$322K |
|
1992
PureCycle Technologies
PCT
$1.41B
| $1.2M | ﹤0.01% |
139,161
-1,496,897
| -91% | -$15.9M |
|
1993
Goosehead Insurance
GSHD
$2.33B
| $1.19M | ﹤0.01% |
16,177
-218,527
| -93% | -$15.6M |
|
1994
Lindsay Corp
LNN
$1.18B
| $1.19M | ﹤0.01% |
10,108
+1,535
| +18% | +$185K |
|
1995
iShares MSCI EAFE Growth ETF
EFG
$17.4B
| $1.19M | ﹤0.01% |
10,449
| – | – |
|
|
GBIO
1996
DELISTED
Generation Bio
GBIO
| $1.19M | ﹤0.01% |
209,641
-367,148
| -64% | -$2.07M |
|
1997
Phreesia
PHR
$780M
| $1.19M | ﹤0.01% |
70,383
+5,587
| +9% | +$115K |
|
|
UNIT
1998
Uniti Group
UNIT
$2.31B
| $1.18M | ﹤0.01% |
168,744
+29,383
| +21% | +$186K |
|
1999
Healthcare Services Group
HCSG
$1.43B
| $1.18M | ﹤0.01% |
61,500
-4,482
| -7% | -$80.6K |
|
2000
Pennant Group
PNTG
$1.34B
| $1.18M | ﹤0.01% |
41,749
+1,282
| +3% | +$34.1K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.